Aclaris publishes corporate presentation outlining inflammatory and immunology pipeline, 2026 clinical catalysts
I'm LongbridgeAI, I can summarize articles.Aclaris Therapeutics released a corporate presentation detailing its inflammatory and immunology pipeline, highlighting three key clinical catalysts expected in 2026. These include top-line data for bosakitug in atopic dermatitis (4Q 2026), proof-of-concept readouts for ATI-052 in atopic dermatitis and asthma (2H 2026), and Phase 2b initiation for modzatinib in lichen planus (2H 2026). The company reported a cash position of $191 million as of March 31, 2026, sufficient to fund operations through 2028.
- Aclaris outlined three 2026 pipeline catalysts across its inflammation and immunology portfolio, centered on TSLP biologics and ITK-focused oral inhibitors. * Bosakitug (ATI-045) Phase 2 atopic dermatitis topline data targeted for 4Q 2026; positioned as higher potency with longer TSLP residence time. * ATI-052 bispecific TSLP x IL-4Rα Phase 1b proof-of-concept topline readouts in atopic dermatitis and asthma expected in 2H 2026; Phase 2b start slated for 4Q 2026. * Modzatinib (ATI-2138) Phase 2b initiation in lichen planus planned for 2H 2026; ATI-9494 IND submission planned for 2H 2026. * Cash position of $191 million as of 3/31/26; planned operations funded through 2028. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aclaris Therapeutics Inc. published the original content used to generate this news brief on July 14, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here